Spectral discrimination of serum from liver cancer and liver cirrhosis using Raman spectroscopy

2011 ◽  
Author(s):  
Tianyue Yang ◽  
Xiaozhou Li ◽  
Ting Yu ◽  
Ruomin Sun ◽  
Siqi Li
Keyword(s):  
Raman Spectroscopy ◽  
Liver Cirrhosis ◽  
Liver Cancer ◽  
Spectral Discrimination

Spectral discrimination of serum from liver cancer and liver cirrhosis using Raman spectroscopy

2011 ◽  
Author(s):  
Tianyue Yang ◽  
Xiaozhou Li ◽  
Ting Yu ◽  
Ruomin Sun ◽  
Siqi Li
Keyword(s):  
Raman Spectroscopy ◽  
Liver Cirrhosis ◽  
Liver Cancer ◽  
Spectral Discrimination

scholarly journals Viral hepatitis and liver cancer

2017 ◽  
Vol 372 (1732) ◽  
pp. 20160274 ◽  
Author(s):  
Marc Ringehan ◽  
Jane A. McKeating ◽  
Ulrike Protzer
Keyword(s):  
Liver Cirrhosis ◽  
Liver Cancer ◽  
Hepatitis B ◽  
Viral Infections ◽  
Current Knowledge ◽  
Primary Liver Cancer ◽  
Oncogenic Viruses ◽  
Chronic Infections ◽  
Future Design ◽  
End Stage

Hepatitis B and C viruses are a global health problem causing acute and chronic infections that can lead to liver cirrhosis and hepatocellular carcinoma (HCC). These infections are the leading cause for HCC worldwide and are associated with significant mortality, accounting for more than 1.3 million deaths per year. Owing to its high incidence and resistance to treatment, liver cancer is the second leading cause of cancer-related death worldwide, with HCC representing approximately 90% of all primary liver cancer cases. The majority of viral-associated HCC cases develop in subjects with liver cirrhosis; however, hepatitis B virus infection can promote HCC development without prior end-stage liver disease. Thus, understanding the role of hepatitis B and C viral infections in HCC development is essential for the future design of treatments and therapies for this cancer. In this review, we summarize the current knowledge on hepatitis B and C virus hepatocarcinogenesis and highlight direct and indirect risk factors. This article is part of the themed issue ‘Human oncogenic viruses’.

Fast and facile analysis of glycosylation and phosphorylation of fibrinogen from human plasma—correlation with liver cancer and liver cirrhosis

2018 ◽  
Vol 410 (30) ◽  
pp. 7965-7977 ◽  
Author(s):  
Tim Nagel ◽  
Florentine Klaus ◽  
Ines Gil Ibanez ◽  
Henning Wege ◽  
Ansgar Lohse ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Liver Cancer ◽  
Human Plasma

scholarly journals The expression of ETAR in liver cirrhosis and liver cancer

2017 ◽  
Vol 18 (9) ◽  
pp. 723-729 ◽  
Author(s):  
Juhong Deng ◽  
Yu Huang ◽  
Ran Tao ◽  
Xiangxue Fan ◽  
Hongyue Zhang ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Liver Cancer

scholarly journals Clinical characteristics of patients with hepatitis B virus related liver cirrhosis and primary liver cancer

2015 ◽  
Vol 23 (17) ◽  
pp. 2798
Author(s):  
Feng Lv ◽  
Yu-Feng Gao ◽  
Jian-Guo Rao ◽  
Wei Zhang ◽  
Gui-Zhou Zou ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Hepatitis B Virus ◽  
Liver Cancer ◽  
Hepatitis B ◽  
Clinical Characteristics ◽  
Primary Liver Cancer ◽  
B Virus

scholarly journals SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews

2020 ◽  
Vol 8 (2) ◽  
pp. e001956
Author(s):  
Shih-Chieh Shao ◽  
Liang-Tseng Kuo ◽  
Rong-Nan Chien ◽  
Ming-Jui Hung ◽  
Edward Chia-Cheng Lai
Keyword(s):  
Type 2 Diabetes ◽  
Liver Cirrhosis ◽  
Liver Cancer ◽  
Systematic Reviews ◽  
Sglt2 Inhibitors ◽  
Liver Fat ◽  
Umbrella Review ◽  
Alcoholic Fatty Liver ◽  
Liver Functions

IntroductionSodium glucose co-transporter 2 (SGLT2) inhibitors have been reported to benefit liver functions in patients with type 2 diabetes (T2D) with non-alcoholic fatty liver disease (NAFLD). The aim of this study is to critically appraise existing systematic reviews in order to consolidate evidence associating the use of SGLT2 inhibitors with beneficial hepatic results for patients with T2D with NAFLD.MethodsThis umbrella review searched relevant published systematic reviews of clinical trials from PubMed and Embase between inception and September 16, 2020. Two independent investigators appraised study quality using AMSTAR2 (Assessment of Multiple Systematic Reviews 2). The hepatic effects from SGLT2 inhibitors were summarized based on liver enzymes, liver fat, liver histology, liver cirrhosis and liver cancer.ResultsOf 25 screened potential systematic reviews, we ultimately included 7 in this study. However, none of them could be rated as being of high methodological quality. Five systematic reviews indicated that SGLT2 inhibitors could effectively decrease liver fat and liver parameters of alanine aminotransferase and gamma-glutamyl transferase in patients with NAFLD. Two systematic reviews indicated that SGLT2 inhibitors could reduce hepatosteatosis, as supported by biopsy-proven evidence of improvement from a small clinical trial, but no evidence of liver fibrosis improvement was found.ConclusionsThere is some association between SGLT2 inhibitor use and observed benefits to liver functions in patients with T2D with NAFLD, although the quality of current systematic reviews remains relatively low. Further evaluation of long-term liver outcomes with SGLT2 inhibitors in cases of liver cirrhosis and liver cancer is warranted.

Sign in / Sign up

Export Citation Format

Share Document